Company: ABUS
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001447028-25-000126
Chunk: 41

Company: Arbutus Biopharma Corp
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 1
Chunk 41
---

Stock-based compensationThe table below summarizes information about the Company’s stock-based compensation for the three and nine months ended September 30, 2025 and 2024 and the expense recognized in the condensed consolidated statements of operations: Three Months Ended September 30,Nine Months Ended September 30,2025202420252024(in thousands, except share and per share data)Stock optionsOptions granted during period557,600 — 5,263,722 4,163,000 Weighted average exercise price$3.39 $— $3.33 $2.49 Restricted stock units (RSUs)Restricted stock units granted during period1,066,609 — 1,968,509 1,316,200 Grant date fair value$3.82 $— $3.58 $2.40 Stock compensation expenseResearch and development$566 $847 $1,495 $3,007 General and administrative636 1,313 1,764 4,347 Total stock compensation expense$1,202 $2,160 $3,259 $7,354 

11.    Segment Reporting

The Company has one reportable segment. The Company’s chief operating decision maker is the Chief Executive Officer and President. The accounting policies of the single segment are the same as those described in the summary of significant accounting policies. The chief operating decision maker assesses performance for the single segment and decides how to allocate resources based on net loss that also is reported on the condensed and consolidated statements of operations and comprehensive income (loss) as consolidated net loss. The chief operating decision maker uses net loss to monitor budget versus actual results and to evaluate the overall cash burn of the business. Three Months Ended September 30,Nine Months Ended September 30,2025202420252024(in thousands)Revenue$529 $1,339 $13,032 $4,597 Less:Research and development employee expense, lab supplies and overhead3,194 6,166 9,927 20,174 Imdusiran IM-PROVE I, II & III clinical trials expense1,073 5,031 4,862 14,430 AB-101-001 Phase 1a/1b clinical trial expense1,134 2,931 4,771 8,927 Other research and development programs expense377 145 675 1,696